BioTie Therapies Corp. Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence
5/10/2013 10:59:53 AM
More...
|
BioTie Therapies Corp.: Selincro Launched in the United Kingdom
5/6/2013 11:10:34 AM
More...
|
Change in the Number of Votes Relating to BioTie Therapies Corp.'s Shares
5/6/2013 9:54:54 AM
More...
|
BioTie Therapies Corp.: Selincro Launched in the United Kingdom
5/6/2013 9:31:47 AM
More...
|
BioTie Therapies Corp.: Selincro Launched in First European Markets
4/22/2013 12:14:36 PM
More...
|
Resolutions of the Annual General Meeting of BioTie Therapies Corp. and Organization of the Board
4/4/2013 11:42:57 AM
More...
|
BioTie Therapies Corp. Presents Tozadenant Phase 2b Data at American Academy of Neurology Annual Meeting
3/21/2013 9:51:03 AM
More...
|
BioTie Therapies Corp.: Selincro (nalmefene) Receives European Marketing Authorization
2/28/2013 9:15:36 AM
More...
|
UCB, Inc. (UCBJF.PK) Licenses Global Rights to Tozadenant in Parkinson's Disease From BioTie Therapies Corp. for $20 Million
2/27/2013 7:14:28 AM
More...
|
BioTie Therapies Corp. Reports Top-Line Data From Clinical Study With Nepicastat (SYN117) in Post-Traumatic Stress Disorder
12/27/2012 8:52:30 AM
More...
|
|